Cancer research

Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001

Retrieved on: 
Tuesday, August 8, 2023
Alternative Medicine, AIDS, Health, Biometrics, Science, Veterinary, Nursing, Medical Supplies, FDA, Diabetes, Surgery, Health Technology, Health Insurance, Research, Vitamins, Supplements, Telemedicine, Virtual Medicine, Other Health, Radiology, Pharmaceutical, Optical, Oncology, Mental Health, Medical Devices, Infectious Diseases, Neurology, Hospitals, Stem Cells, Genetics, Practice Management, COVID-19, Fitness & Nutrition, Physical Therapy, Dental, Managed Care, Clinical Trials, General Health, Cardiology, Biotechnology, Cancer research, Health care, CTE, Drug development, Lymphoid leukemia, Bone marrow, Cancer, Northwest Biotherapeutics, CAR, Cancer Research UK, CTA, CD19, Patient, MHRA, Pharmaceutical industry

Aleta Biotherapeutics (Aleta), a privately-held immuno-oncology company with a platform of CAR T-Cell Engagers (CTE) which enable cell therapies to improve outcomes for patients with cancer, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately-held immuno-oncology company with a platform of CAR T-Cell Engagers (CTE) which enable cell therapies to improve outcomes for patients with cancer, announces that the U.K.
  • Medicines and Healthcare products Regulatory Agency (MHRA) has granted clinical trial authorization (CTA) to evaluate investigational biologic ALETA-001 in a Phase 1/2 clinical trial in the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T-cell therapy.
  • Aleta’s lead program, ALETA-001 has clinical support and funding from its collaboration partner, Cancer Research UK’s Centre for Drug Development, which has sponsored and will conduct the Phase 1/2 clinical trial.
  • “The authorization to clinically evaluate, in collaboration with Cancer Research UK, the potent activity of ALETA-001, our lead biologic CAR T-Cell Therapy Engager, marks important progress for the entire global oncology community - especially patients,” commented Paul Rennert, Ph.D., Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.

Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage Research Portfolio

Retrieved on: 
Thursday, August 3, 2023
Science, Professional Services, Research, Finance, Cambridge Institute for Sustainability Leadership, Molecular biology, GSK, LLP, University, Genetics, Cancer research, University of Cambridge, Cancer, General partnership, Acquisition, Patient, FRS, Cancer Research UK, Drug discovery, Therapy, Gene, Oligonucleotide, DSM-IV codes, Genome, Pharmaceutical industry, Ahrén, Adrasteia, Insming, Biology, Fellow of the Academy of Medical Sciences

“Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.

Key Points: 
  • “Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.
  • With Insmed, we’re no longer dreaming big, we’re going big.”
    Adrestia’s synthetic rescue platform uses whole genome assays to identify drug targets for genetic diseases in a wide network of functionally connected genes.
  • Sir Steve is University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • J.P. Morgan Securities plc acted as exclusive financial adviser to Adrestia, and Goodwin Procter (UK) LLP acted as Adrestia’s legal counsel.

NK:IO Raises £1.2M, Bringing Total Seed Funding to £5.1M, to Advance Pioneering NK Cell Therapy

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Interim, Cell biology, Gene, IO, Cancer research, Unitus Seed Fund, Cancer, Cancer Research UK, Research, Patient, Hugh, Innovation, Engineering, Cell, Neoplasm, Imperial College London, Entrepreneurship, Immunology, Ovarian cancer, Therapy, Catapult, Pharmaceutical industry, NK, Chemistry

This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development.

Key Points: 
  • This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development.
  • NK:IO is based on pioneering discoveries in NK cell biology from Hugh J M Brady, Professor of Immunology and Matt Fuchter, Professor of Chemistry, at Imperial College.
  • NK:IO is exploiting these in its unique platform which activates blood stem cell progenitors to yield industry-leading NK cell tumour-killing potency and very high yield cell production, which it believes will be transformative in cancer cell therapy.
  • This includes development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult, whose mission is to support the UK’s cell and gene therapy industry.

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

Retrieved on: 
Monday, July 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Exercise, Injection, BS, FRCP, VAC, Vaccination, Reverse transcriptase, Neoplasm, Cancer research, Survival, Geographic atrophy, Cancer, Lung cancer, Cancer Research UK, Research, Doctor of Philosophy, ID, Trial of the century, Șaeș, Publication, MD, Patient, University, TASE, University of Birmingham, NYSE American, Drug development, VAC2, Toxic epidermal necrolysis, Lineage Cell Therapeutics, Immunology, Therapy, Disease, Safety, Vaccine, Medical imaging, Lineage, Immunotherapy, NSCLC

All eight subjects enrolled and treated completed the full per protocol vaccination regimen, which consisted of six-consecutive weekly intradermal (ID) injections of 1 x 107 viable VAC2 cells.

Key Points: 
  • All eight subjects enrolled and treated completed the full per protocol vaccination regimen, which consisted of six-consecutive weekly intradermal (ID) injections of 1 x 107 viable VAC2 cells.
  • Overall, VAC2 was well-tolerated, there were no unexpected SAEs, and there were no dose limiting toxicities.
  • Brian Culley, Chief Executive Officer of Lineage, added: “The conclusion of this partnered study represents an important milestone for Lineage’s allogeneic cell therapy pipeline.
  • Lineage, Cancer Research UK, and the participating investigators intend to present these data at future medical and scientific conferences and submit publications to relevant journals for peer review.

Kytopen Announces Collaboration with leading bioengineer Omid Veiseh, PhD. to Fuel Genome Engineering Research and Accelerate Cell Therapy Discovery

Retrieved on: 
Tuesday, July 11, 2023
DNA, CRISPR, Partnership, Rice University, Rice University Electrical and Computer Engineering, Cancer research, Biotechnology, Gene editing, Cancer, Infection, Cell, CCO, College of Engineering (KNUST), Doctor of Philosophy, Autoimmunity, Associate, Messenger, Genome-wide CRISPR-Cas9 knockout screens, CDMO, Engineering, Biological engineering, Synthetic biology, Wound healing, Pharmaceutical industry, Vaccine

This collaboration aims to drive cutting-edge research in genome engineering and expedite the discovery of novel cell therapies.

Key Points: 
  • This collaboration aims to drive cutting-edge research in genome engineering and expedite the discovery of novel cell therapies.
  • "Cell therapy discovery holds tremendous promise for addressing challenging diseases such as cancer and rare disorders.
  • Translational Medical Research Centers, such as Rice University, play a vital role in spearheading innovative medical therapeutic research."
  • "This collaboration exemplifies our dedication to solving cell therapy manufacturing problems at the discovery stage."

Appia Bio Expands Leadership Team With Sylvaine Cases, Ph.D. Appointed Chief Business Officer and Alex Babayan, Ph.D. as Vice President, Head of Regulatory Affairs

Retrieved on: 
Wednesday, June 28, 2023
Amgen, Private sector, ACUA, University, University of California, Irvine academics, Cancer research, Cancer, Axicabtagene ciloleucel, Janssen, Head, University of California, Allotransplantation, Research, Stem cell, TCR, Institut Gustave Roussy, Health, Arete, CAR, Metabolism, Patient, Investment, CBO, Biology, LOS, Gladstone Institutes, Therapy, Kite, BLA, IND, Tumor microenvironment, Bangladesh Technical Education Board, Pharmacology, Pharmaceutical industry, Sanofi

LOS ANGELES, June 28, 2023 /PRNewswire/ -- Appia Bio, Inc., a biotechnology company developing allogeneic chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-NKT) cell therapies from hematopoietic stem cells (HSCs) for patients with cancer, today announced the appointments of Sylvaine Cases, Ph.D. as chief business officer (CBO) and Alex Babayan, Ph.D. as vice president, head of regulatory affairs.

Key Points: 
  • "We are delighted to have Sylvaine and Alex join the Appia Bio team.
  • Sylvaine is a thoughtful business executive with deep understanding of our industry from both sides of the table.
  • Alex brings long-term considered insight based on his broad global regulatory affairs experience in cell therapy.
  • Dr. Babayan joins Appia Bio from Instil Bio where he was vice president and head of regulatory affairs.

Susan G. Komen® Announces 2023 Grants to Accelerate Research Discoveries and Improve Outcomes for Breast Cancer Patients

Retrieved on: 
Wednesday, June 28, 2023
TNBC, DNA, Indiana University, University, Grant, Doctor of Philosophy, Cancer research, Eric, Pietenpol Air Camper, Vanderbilt University Medical Center, Research, Oncology, Government, Harvard Medical School, Puberty, Biochemistry, Patient, Breast cancer, Risk, Drug combination, Biology, Inclusion, GC, Disease, Pharmaceutical industry, Dietary supplement, Birth control, Nursing, Medicine

DALLAS, June 28, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced the awarding of 49 new grants to researchers at 28 leading institutions in the U.S. The $19.3 million in new grants support Komen's mission to end breast cancer through funding two focus areas: advancing precision medicine and eliminating disparities in breast cancer outcomes, while continuing Komen's commitment to supporting the next generation of diverse leaders in breast cancer research.

Key Points: 
  • The $19.3 million in new grants support Komen's mission to end breast cancer through funding two focus areas: advancing precision medicine and eliminating disparities in breast cancer outcomes, while continuing Komen's commitment to supporting the next generation of diverse leaders in breast cancer research.
  • Of the $19.3 million awarded:
    More than 65% supports research focused on the most aggressive breast cancers, including recurrent and metastatic breast cancer.
  • Nearly 40% supports research focused on understanding the causes and finding solutions to eliminate, reduce and address breast cancer disparities.
  • Komen has now invested nearly $1.1 billion in breast cancer research, the largest collective investment of any breast cancer nonprofit and second only to the U.S. government.

The V Foundation for Cancer Research Announces the First Class of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research

Retrieved on: 
Tuesday, June 27, 2023
Pancreatic cancer, Tobacco Products Scientific Advisory Committee, VCU Massey Cancer Center, Male, University, Mohammed V Foundation for Solidarity, Cancer research, COVID-19, NYU, Cancer, Jim Valvano, CDK7, Woman, Research, Salk Institute for Biological Studies, RNA, Assistant, Science, Cooper University Hospital, UCSF, Patient, Cancer Treatment Centers of America, Engineering, Melanoma, Dartmouth Cancer Center, Washington University School of Medicine, University of British Columbia, Ovarian cancer, Aichi M6A, Female, Prostate cancer, Dana–Farber Cancer Institute, Pharmaceutical industry, Nursing, Vaccine, Birth control, Doctor of Philosophy, MD

CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research. This landmark initiative is helping to counteract longstanding gender disparities in research by investing $8 million in the groundbreaking work of 11 women scientists leading the charge in cancer research.

Key Points: 
  • CARY, N.C., June 27, 2023 /PRNewswire/ -- The V Foundation for Cancer Research, a premier cancer research charity, proudly announces the first recipients of A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research.
  • We are not only advancing vital cancer research, but we're working to encourage more women to pursue careers in science.
  • The setbacks endured throughout the pandemic will have long-term for women in cancer research.
  • Recognizing these disparities, the V Foundation for Cancer Research developed A Grant of Her Own: The Women Scientists Innovation Award for Cancer Research to amplify female representation and encourage more women-led breakthroughs in this field.

Adrestia Co-Founder Professor Steve Jackson Named Knight Bachelor for Services to Innovation and Research

Retrieved on: 
Friday, June 16, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Cambridge Institute for Sustainability Leadership, DNA, University, University of California, Berkeley, Doctor of Philosophy, Life, CSO, Cancer research, Medicine, Cancer, Royal Society, Multimedia, Royal, AstraZeneca, Knight Bachelor, DNA repair, UC, Patient, Cancer Research UK, United Kingdom, Therapy, PARP, Gene, Birthday Honours, DSM-IV codes, Genome, Knight, Management, Pharmaceutical industry, Adrasteia, Biology

Professor Jackson is a noted scientist-entrepreneur and holds several academic positions in addition to being the Chief Scientific Officer of Adrestia.

Key Points: 
  • Professor Jackson is a noted scientist-entrepreneur and holds several academic positions in addition to being the Chief Scientific Officer of Adrestia.
  • View the full release here: https://www.businesswire.com/news/home/20230616268448/en/
    Professor Steve Jackson FRS FMedSci (Photo: Business Wire)
    “It is humbling to join a group with such a long history,” said Professor Jackson.
  • Professor Jackson is the University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • As a Knight Bachelor, Professor Jackson may use the prefix “Sir” and will formally be presented with this honour in the coming months.

Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research

Retrieved on: 
Saturday, June 3, 2023
Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Science, Health, Partnership, American Oncology Institute, Cancer research, Clinical trial, Cancer, Hope, Intelligence, Multimedia, ASCO, Patient, Physician, Algorithm, Clinical research, Medicine, AI, Pharmaceutical industry, Medical imaging

Massive Bio , a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI) , a premier provider of cutting-edge cancer care.

Key Points: 
  • Massive Bio , a leader in leveraging artificial intelligence and concierge services to empower cancer patients, is thrilled to announce a non-exclusive partnership with The Oncology Institute (TOI) , a premier provider of cutting-edge cancer care.
  • View the full release here: https://www.businesswire.com/news/home/20230603005001/en/
    Massive Bio and The Oncology Institute (TOI) Forge Partnership to Revolutionize Cancer Care and AI-enabled Cancer Research (Photo: Business Wire)
    Under this visionary collaboration, Massive Bio will support TOI with evaluating the eligibility of patients for TOI's active clinical trial portfolio, utilizing their cooperative business model driven by AI and precision medicine.
  • "We are incredibly excited about joining forces with The Oncology Institute ," said Selin Kurnaz, Ph.D., CEO of Massive Bio.
  • Furthermore, this collaboration will expand the scope of cancer research through Massive Bio's recent ChatGPT-powered chatbots for oncology research release during ASCO 2023.